Conference abstract · 18 Nov 2025
Research articlePublished 6 Dec 2021
Human Epidermal Growth Factor Receptor-2(HER-2) Expression in Sri Lankan Gastric Adenocarcinoma Patients: Analysis of the Concordance of HER2 Expression and Survival Based on Silver In-Situ Hybridization (SISH)
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Accurate HER2 status is crucial for Gastric Adenocarcinoma (GC) patient selection for antiHER2 therapy. It is assessed Immunohistochemically (IHC) for protein expression, and by Silver In-Situ Hybridization (SISH) for gene copy number. This study aimed to evaluate the concordance of HER2 status by IHC/SISH analyses and HER2-SISH based survival. Methods: This prospective study includes 145 GC’s (excluding gastro-oesophageal-junction tumours) from the National Hospital of Sri Lanka with defined demographic, clinical-radiological-pathological characteristics. HER2- IHC was assessed by DAKO A0485, RealTM Envision system and interpreted using Ruschoff criteria. HER2-SISH was assessed with INFORM HER2 dual ISH DNA Probe Cocktail. Concordance between HER2 IHC/SISH results was determined by Cohen’s kappa statistics. The association between the survival and HER2-SISH positivity was evaluated using the cox-regression method. Adjustments were done for age, gender, Lauren classification, tumour location and the tumour staging. Results: The 69 gastrostomies and 76 biopsies, 8.3% (n=12) were HER2-IHC positive (n=7, +2 and n=5, +3). HER2- SISH positivity was 4.8% (n=7). All IHC+3 were SISH positive, while two +2 cases were SISH positive. Concordance for IHC 0, +1, +3 were 100%. There was a significant overall correlation (kappa=0.72, p<0.001) between HER2-IHC and HER2-SISH indicating substantial concordance. The mean overall survival of HER2-SISH negative and positive patients were 41.7(0-210) and 14.6(3-51) weeks respectively, after a mean duration of patient follow up for 40.4 weeks (range 0-210). Survival was relatively lower (p=0.001) in the group with HER2-SISH positivity. Conclusion: HER2-IHC was well concordant with HER2-SISH for 0, +1, +3 scores and could be used for treatment and prognostication in low resource settings, where SISH facility is unavailable. HER2-IHC+2, without gene amplification may be due to transcriptional activation by other genes or post-transcriptional events, mandating further evaluation by SISH. Survival of GC patients is significantly affected by HER2-SISH positive status. Core tip-HER2 positive Gastric Carcinomas (GC) are usually associated with more aggressive. Aim of this study is to find out HER-2 positivity based on IHC and SISH in Sri Lankan Gastric adenocarcinomas which was not described previously.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Hepatology and Gastrointestinal disorders.
Conference abstract · 18 Nov 2025
Health benefits of probiotic bacteria
Conference abstract · 18 Nov 2025
Comprehensive case study of periampullary carcinoma in a 70-year-old patient: Management, nursing interventions, and recovery
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Hepatology and Gastrointestinal disorders
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Duminda Subasinghe”
- BylineArticles whose byline prints “Nathan Acott”
- BylineArticles whose byline prints “Pasyodun Koralage Buddhika Mahesh”
- BylineArticles whose byline prints “Sivasuriya Sivaganesh”
- BylineArticles whose byline prints “Ananthi Samarasinghe”
- BylineArticles whose byline prints “Mariyan Priyanthi Kumarasinghe”
- BylineArticles whose byline prints “Dharmabandhu Nandadeva Samarasekera”
- BylineArticles whose byline prints “Menaka Dilani Samarwickrema Lokuhetty”
